Search Results - samir+khleif

1 Results

Sort By:

PD1+CD38+ CD8 T-cells, a marker for anti-PD1 therapy resistance and selection marker for treatment or continuation of treatment of patients, and a target to reverse resistance

PD1+CD38+ CD8 T-cells, a marker for anti-PD1 therapy resistance and selection marker for treatment or continuation of treatment of patients, and a target to reverse resistance Current state of the artA number of new checkpoint inhibitors are used in cancer therapy. PD-1 inhibitors such as Pembrolizumab (Keytruda), Nivolumab (Opdivo), and Cemiplimab...

Published: 8/29/2024 | Inventor(s): Samir Khleif, Vivek Verma, Seema Gupta

Keywords(s):

Category(s): Therapeutics